Latest News - AbbVie
Top Corporates Hub
AbbVie
Fibromyalgia Market Analysis Report 2025-2035 | Key Players Drive Competition in Expanding Treatment Options
01.08.2025 09:00
Fibromyalgia, a complex chronic pain disorder marked by widespread pain, fatigue, and cognitive issues, is witnessing evolving treatment advancements. The global market is experiencing growth through novel drugs targeting central sensitization, increased use of digital health tools, and personalized medicine. Enhanced diagnostic criteria are aiding improved disease management, although challenges like underdiagnosis and limited treatment efficacy persist. Key areas like North America and Europe
Tenosynovitis Market Research Report 2025-2035 | Rising Demand for Tenosynovitis Treatment Amid Increasing Rheumatoid Arthritis Cases
01.08.2025 08:30
Embracing Innovation in Tenosynovitis Treatment: The global Tenosynovitis market is advancing rapidly, driven by the rising prevalence of inflammatory diseases like rheumatoid arthritis. As aging populations increase, demand grows for effective treatments to manage this tendon sheath inflammation. Biologic and targeted therapies, including TNF and IL-6 inhibitors, are at the forefront, alongside non-invasive options like PRP therapy. Leading companies such as Pfizer and AbbVie are fueling innova
AbbVie Inc (ABBV) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...
01.08.2025 07:20
AbbVie Inc (ABBV) surpasses expectations with robust sales from Skyrizi and Rinvoq, while navigating Humira declines and aesthetics challenges.
The Fed Isn't Sure About The Economy Anymore
31.07.2025 08:45
Explore the latest FOMC insights on US growth, inflation, and rate cut expectations. Discover why defensives remain key amid market gains.
Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Report 2025: Global Trends, Revenue, and Market Dynamics
31.07.2025 08:12
The global IBS and IBD therapeutics market is set to grow from $33.3 billion in 2025 to $52.6 billion by 2030, at a 9.6% CAGR. The report analyzes market trends, key players, and regional impact, offering insights into drug classes and business strategies of industry leaders like AbbVie and Amgen. Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The "Ir
AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
30.07.2025 12:31
AbbVie (NYSE: ABBV) today announced positive topline results from the first of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean baseline SALT score of 83.8 (approximately 16% scalp hair coverage).1
Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever
30.07.2025 08:20
Being a great investor doesn't have to be complicated or expensive.
AbbVie (ABBV) Reports Q2: Everything You Need To Know Ahead Of Earnings
30.07.2025 03:14
Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings this Thursday before market open. Here’s what investors should know.
AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
29.07.2025 12:00
AbbVie (NYSE: ABBV) announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the fixed-duration, all-oral combination regimen of VENCLEXTA® (venetoclax) and acalabrutinib in previously untreated patients with CLL, offering CLL patients another VENCLEXTA combination regimen with the potential for time-limited treatment.The submission is based on the positive results from the Phase 3 AMPLIFY trial.1 The combination regimen of VENCLEX
QDEF: Dividend ETF With Little To Show
23.07.2025 14:42
FlexShares Quality Dividend Defensive Index Fund ETF has a portfolio of 127 dividend stocks based on a quality score and beta optimization. Read why QDEF is a Buy.
Atopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances
23.07.2025 08:08
The atopic dermatitis market, valued at USD 9.33 billion in 2024, is projected to grow at a CAGR of 15.10%, reaching USD 38.07 billion by 2034. Key drivers include increasing prevalence, FDA approvals like LEO Pharma's tralokinumab-ldrm, and novel treatments. Major players include AbbVie, Pfizer, and Regeneron. Atopic Dermatitis Market Atopic Dermatitis Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis Market Report and Forecast 2025-2034" report has been added to ResearchA
Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT
20.07.2025 04:35
AbbVie Inc. (NYSE:ABBV) is one of the best long term low volatility stocks to buy now. On July 10, Morgan Stanley analyst Terrence Flynn reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) and set a price target of $250.00. AbbVie Inc. (NYSE:ABBV) reported positive fiscal Q1 2025 results that support the optimistic outlook, with adjusted […]
Why AbbVie (ABBV) Remains a Dividend Standout in the Pharma Sector
19.07.2025 01:35
AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. AbbVie Inc. (NYSE:ABBV) stands out as a major player in the pharmaceutical industry, with a broad range of approved treatments. Among its most significant offerings are the immunology drugs Skyrizi and Rinvoq, which are expected to contribute to revenue growth […]
Tax Court Breaks New Ground On The Deductibility Of Termination Fees With AbbVie Ruling
15.07.2025 10:14
On June 17, 2025, the Tax Court opinion in AbbVie Inc. and Subsidiaries v. Commissioner of Internal Revenue was issued,1 holding that the approximately $1.6 billion termination fee AbbVie paid to its...
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?
11.07.2025 14:00
AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.
IGI and AbbVie sign licence deal for cancer and autoimmune therapy
11.07.2025 08:38
IGI Therapeutics will be entitled to $1.225bn on reaching development milestones and targets.
India's Glenmark Pharma soars 10% to record high on AbbVie cancer treatment licensing deal
11.07.2025 03:55
(Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after its unit signed a licensing deal with U.S. peer AbbVie for its early-stage blood cancer treatment. The stock was the top percentage gainer on the Nifty Pharma index, which traded 1.1% higher compared to a 0.4% loss in the benchmark Nifty 50. AbbVie will get the exclusive rights to develop and commercialise ISB 2001 in North America, Europe, Japan and Greater China, according to the deal.
India's Glenmark Pharma soars 10% to record high on AbbVie cancer licensing deal
11.07.2025 01:03
Shares of India's GlenmarkPharmaceuticals jumped 10% to a record high on Friday,a day after its unit signed a licensing deal with U.S. peerAbbVie for its early-stage blood cancer treatment. ...
India's Glenmark Pharma unit, AbbVie sign exclusive licensing pact
10.07.2025 10:10
India's Glenmark Pharmaceuticalssaid on Thursday its innovation arm, Ichnos GlenmarkInnovation , and AbbVie have signed an exclusivelicensing agreement for IGI's cancer treatment, adding to...
AbbVie and Ichnos Glenmark Innovation Announce Exclusive Global Licensing Agreement for ISB 2001, a First-In-Class CD38xBCMAxCD3 Trispecific Antibody
10.07.2025 08:51
AbbVie and IGI Therapeutics SA announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT®? protein platform, for oncology and...